Journal article
Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy
- Abstract:
-
Programmed cell death ligand 1 (PD-L1) interacts with programmed cell death protein-1 (PD-1) as an immune checkpoint. Reactivating the immune response by inhibiting PD-L1 using therapeutic antibodies provides substantial clinical benefits in many, though not all, melanoma patients. However, transcriptional suppression of PD-L1 expression as an alternative therapeutic anti-melanoma strategy has not been exploited. Here we provide biochemical evidence demonstrating that ultraviolet radiation (U...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 147.6KB)
-
(Accepted manuscript, pdf, 104.7KB)
-
(Accepted manuscript, pdf, 103.8KB)
-
(Accepted manuscript, tiff, 752.5KB)
-
(Accepted manuscript, pdf, 57.1KB)
-
(Accepted manuscript, pdf, 227.5KB)
-
(Accepted manuscript, pdf, 115.0KB)
-
(Accepted manuscript, pdf, 209.9KB)
-
- Publisher copy:
- 10.1038/s41388-018-0314-0
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Funding
+ National Natural Science Foundation of China
More from this funder
Grant:
81673977 for 2016 for XM
+ Priority Academic Program Development of Jiangsu Higher Education Institutions
More from this funder
Grant:
IntegrationofChinese
WesternMedicinegrant(PC
Bibliographic Details
- Publisher:
- Springer Nature Publisher's website
- Journal:
- Oncogene Journal website
- Volume:
- 37
- Pages:
- 4941–4954
- Publication date:
- 2018-05-22
- Acceptance date:
- 2018-04-20
- DOI:
- EISSN:
-
1476-5594
- ISSN:
-
0950-9232
- Source identifiers:
-
846503
Item Description
- Keywords:
- Pubs id:
-
pubs:846503
- UUID:
-
uuid:d0985f16-1fd8-4bd3-8a63-26e8b0d45bee
- Local pid:
- pubs:846503
- Deposit date:
- 2018-05-08
Terms of use
- Copyright holder:
- Zhu et al
- Copyright date:
- 2018
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from Springer Nature at: https://doi.org/10.1038/s41388-018-0314-0
If you are the owner of this record, you can report an update to it here: Report update to this record